Hospira 0409-7419-03 10% LMD i

我们诺博莱德公司作为Hospira公司的经销商，先介绍一下Hospira公司：
美国Hospira www.hospira.comHospira，Inc. 是一家专注于 Advancing Wellness(TM) 的全球性专业药品及药物供应公司。作为专业注射用仿制药领域的全球lingdaozhe，Hospira 提供了最广泛的急性病治疗和肿瘤注射仿制药组合之一以及用于输液治疗和医药管理的整合解决方案。通过其产品，Hospira 帮助改善了患者护理的安全性、降低了成本并提高了效率。该公司总部位于美国伊利诺伊州莱克福里斯特，共有约14000名员工。
Hospira 0409-7419-03 10% LMD in 0.9% Sodium Chloride Injection DEX40右旋糖酐，产品简介：
产品品牌：Hospira
产品名称：DEX40右旋糖酐
英文名称：0% LMD in 0.9% Sodium Chloride Injection DEX40
产品规格：500mL/包
我们北京诺博莱德科技有限公司作为Hospira公司的经销商为客户提供，正规进口，保证原装正品，货期稳定，折扣好的服务标准。
10% LMD in 5% Dextrose Injection(Dextran 40 in Dextrose Injection, USP)10% LMD in 0.9% Sodium Chloride Injection(Dextran 40 in Sodium Chloride Injection, USP)Low Molecular Weight Dextran forIntravenous AdministrationFlexible Plastic ContainerRx onlyDESCRIPTIONLMD (dextran 40) is a sterile, nonpyrogenic preparation of low molecular weightdextran (average mol.wt. 40,000) in 5% Dextrose Injection or 0.9%SodiumChlorideInjection. It is administered byintravenous infusion.Also described as low viscous or low viscosity dextran, dextran 40 is prepared by acid hydrolysis anddifferential fractionation of a crudemacromolecular polysaccharide produced from the fermentation ofsucrose by the bacterium, Leuconostoc mesenteroides(strain B-512). The crude material is composed oflinked glucose units. In the fraction represented bydextran 40, 80% of the molecules have a molecularweight ranging from 10,000 to 90,000 (average approximay 40,000) when measured by a lightscattering method. More than 90% of the linkages are of the 1,6 alpha glucosidic, straight chain type.Each 100 mL of 10% LMD (dextran 40) in 5% Dextrose Injection contains 10 g dextran 40 and 5 gdextrose hydrous in water for injection. Total osmolar concentration is 255 mOsmol/liter (calc.); pH is 4.4(3.0 to 7.0).Each 100 mL of 10% LMD (dextran 40) in 0.9% Sodium Chloride Injection contains 10 g dextran40 and 0.9 g sodium chloride in water for injection. Total osmolar concentration is 310 mOsmol/liter(calc.); pH is 4.9 (3.5 to 7.0) (may contain sodium hydroxide and/or hydrochloric acid for pH adjustment).Electrolyte concentration per liter: Na 154 mEq; Cl ? 154 mEq (not including ions for pH adjustment).The solutions contain no bacteriostat, antimicrobial agent or added bufers (except for pH adjustment)and are intended only for single-dose injection. When smaller doses are required the unused portionshould be discarded.10% LMD (dextran 40) is an artificial colloid pharmacologically classified as a plasma volumeexpander; 5% Dextrose Injection isa fluid and nutrient replenisher; 0.9% Sodium Chloride Injection is aluid and electrolyte replenisher.Dextran 40 is a linear glucose polymer (polysaccharide) chemically designated
The structural formula for dextran (repeating unit) is:Dextrose, USP is chemically designated D-glucose monohydrate (C6H12O6• H2O), a hexose sugarfreely soluble in water.Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble inwater.Water for Injection, USP is chemically designated H
2O.The flexible plastic container is fabricated from a specially formulatedpolyvinylchloride. Water canpermeate from inside the container into the overwrap but not in amounts sufficient to affect the solutionsignificantly. Solutions inside the plastic container also can leach out certain of the chemical componentsof the plastic in very small amounts before the expiration period is attained. However, safety of the plastichas been confirmed by tests in animals according to USP biological standards for plastic containers.
CLINICAL PHARMACOLOGY
The fundamental action of LMD (dextran 40) is the
enhancement of blood flow, particularly in themicrocirculation. This enhancement is due to:
1. Its primary effect of volume expansion with resultant hemodilution;
2. Maintenance of the electronegativity of red blood cells;
3. Coating of red blood cells and plaets;
4. Increase in the suspension stability of blood;
5. Decrease in the viscosity of blood.
It should be emphasized that the above
effects are not exerted separay,but conjointly they result in theenhancement of blood flow.LMD, used in the treatment of shock, produces significant increases in blood volume, central venouspressure, cardiac output, stroke volume, blood pressure and urinary output. It reduces blood viscosity,
peripheral resistance and improves peripheral blood flowwith the release of sequestered blood cells,thereby increasing venous return to the heart.When used as part of the pump prime for extracorporeal procedures, LMD, as compared to wholeblood, albumin 5%, or whole blood plus 5% dextroseand water, leads to lessdestruction of red bloodcells and plaets, reduces intravascular hemagglutination and maintains erythrocyte electronegativity.
The infusion of LMD (dextran 40) during and after surgical trauma reduces the incidence of deepvenous thrombosis (DVT) and pulmonary embolism (PE) inpatients subject to surgical procedures with ahigh incidence of thromboembolic complication. Unlike antithrombogenic agents of the anticoagulanttype, LMD does not achieve its effect so much byblocking fibrinogen-fibrin conversion but acts bysimultaneously inhibiting other mechanisms essential to thrombus formation such as vascular stasis andplaet adhesiveness and by altering the structure and thereby the lysability of fibrin clots.Histopathological studies have shown that the development of a mural plaet thrombus is the firststage of thrombus formation not only in the arterial, but also in the venous system. A number of studieshave further shown that many patients who develop thromboembolic complicationsshowan abnormallyhigh plaet adhesiveness. Infusion of LMD has been shown to reduceplaet adhesiveness as measuredby variousin vitrotests on blood samples obtained from humansand to inhibit thegrowth of a muralplaet thrombus at the site of experimental (laser beam) injury in the rabbit’s ear chamber.Studies have shown an increase in the lysability of thrombi formed in the presence of dextran. Aconsistent and characteristic alteration in fibrin structure has been observed when fibrin is formed in thepresence of dextran, and further experiments demonstrated such fibrinto be more susceptible to plasmindigestion. Other studies have shown that dextran infused into patients during surgery increases thelysability ofex vivothrombi. Controlled clinical trials have shown that thrombi in patients treated withdextran have a more pronounced tendency to undergo lysis as determined by phlebography.LMD is evenly distributed in the vascular system. Its distribution according to molecular weight shiftstoward higher molecular weights as the smaller molecules are excreted by the kidney. In normovolemicsubjects, approximay 50% is excreted within 3hours, 60% is excreted within 6 hours and about 75%within 24 hours. Reabsorption of dextran by the renaltubules is negligible. The unexcreted molecules ofdextran diffuse into the extravascular compartment and are temporarily taken up by thereticuloendothelial system. Some of these molecules are returned to the intravascular compartment via thelymphatics. Dextran is slowly degradedby the enzyme dextranase to glucose.
Solutions containing carbohydrate in the form ofdextrose restore blood gluc
ose levels and providecalories. Carbohydrate in the form of dextrose may ai
d in minimizing liver glycogen depletion and exertsa protein sparing action. Dextroseinjected parenterally undergoes oxidation to carbon dioxide and water.
Sodium chloride in water dissociates to provide sodium (Na ) and chloride (Cl ? ) ions. Sodium (Na )is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte
disturbances. Chloride (Cl ? ) has an integral role
in buffering action when oxygen and carbon dioxide
exchange occurs in red blood cells. The di
stribution and excretion of sodium (Na) and chloride (Cl ? ) are
largely under the control of the kidney, which
maintains a balance between intake and output.
Water is an essential constituentof all body tissues and accounts for
approximay 70% of total body
weight. Average normal adult daily requirement ranges from two to three lite
rs (1.0 to 1.5 liters each forinsensible water loss by perspiration and urine production).
Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily
on the concentration of electrolytes in the body compartments and sodium (Na) plays a major role inmaintaining physiologic equilibrium.INDICATIONS AND USAGELMD (dextran 40) is indicated for use in the adjunctive treatment of shock or
impending shock due tohemorrhage, burns, surgery or other trauma. It is not indicated as a replacement for whole blood or bloodcomponents if they are available. Itshould not replace other forms of therapy known to be of value in the
treatment of shock.LMD is also indicated for use as a priming fluid, either as a sole prime or as an additive, in pumpoxygenators during extracorporeal circulation.
LMD is also indicated for usein prophylaxis of venous thrombosis and pulmonary embolism inpatients undergoing procedures knownto be associated with a high incidence of thromboemboliccomplications, such as hip surgery.

以下是Hospira 0409-7419-03 10% LMD in 0.9% Sodium Chloride Injection DEX40右旋糖酐,相关产品，如需其它型号产品请详询客服

产品品牌	产品货号	产品名称	产品规格
Corning	88-581-CM	康宁淋巴细胞无血清培养基	1L/瓶
Corning	88-551-CM	KBM551, serum-free medium for DC and CIKDC CIK细胞无血清培养基	1L/瓶
LONZA	04-418Q	淋巴细胞-造血干细胞无血清培养基	1L/瓶
corning	88-570-kit	1.2 NK细胞活化扩增培养套装	套装
TAKARA	T100B	RetroNectin®RetroNectin Recombinant Human Fibronectin Fragment 重组人纤粘连蛋白	2.5mg
TAKARA	T100A	RetroNectin®RetroNectin Recombinant Human Fibronectin Fragment 重组人纤粘连蛋白	0.5mg
PeproTech /BioGems	05121-25-500	Ant Human CD3 mAb (克隆号0KT3)	500ug
PeproTech /BioGems	10311-25-500	Anti Human CD28 mAb (克隆号CD282)	500ug
PeproTech	AF-200-01A	重组人IL1-a(Animal Free)	10ug/100ug
PeproTech	AF-300-03	重组人GM-CSF (Animal Free)	20ug/100ug
PeproTech	AF-300-01A	重组人TNF-a(Animal Free)	50ug/支
PeproTech	AF-300-02	重组人IFN-V(Animal Free)	100ug/支
PeproTech	AF-200-02	重组人IL-2 (Animal Free)	50ug/100ug
PeproTech	AF-200-04	重组人IL-4 (Animal Free)	20ug/100ug
PeproTech	AF-200-07	重组人IL-7 (Animal Free)	10ug/支
PeproTech	AF-200-15	重组人IL-15 (Animal Free)	10ug/支
PeproTech	AF-200-21	重组人IL-21 (Animal Free)	10ug/支
BD	Mouse Anti-Human CD3	FTIC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD4	FIIC/PE/APC/PerCP-CyTM5.5/APC-CYTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD8	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD16	FITC/PE/APC/PerCP-CYTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD56	FITC/PE/APC/PerCP-CYTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human FoxP3	FITC/PE/APC/PerCP-CYTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD14	FITC/PE/APC/PerCP-CYTM5.5/APC-Cy7TM/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD19	FITC/PE/APC/PerCP-CyTM5.5/APC-Cy7TM/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD20	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD80	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti-Human CD86	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse Anti- Human CD83	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	BD Mouse Anti-Human HLA-DR	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse IgG1, K Isotype Control	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse IgG2a, K Isotype Control	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	25/50/100Test
BD	Mouse IgG2b, K Isotype Control	FITC/PE/APC/PerCP-CyTM5.5/APC-CyTM7/BV421/V450	50/100Test
GE	17-1440-02	Ficoll Paque PLUS,1 078g/ml淋巴细胞分离液	6X100mL
GE	17-1440-03	Ficoll Paque PLUS,.1 078g/ml淋巴细胞分离液	6X500mL
GE	17-5442-02	Ficoll Paque PREMIUM,1 .078g/mL淋巴细胞分离液	6X100mL
GE	17-5442-03	Ficoll Paque PREMIUM,1.078g/ml淋巴细胞分离液	6X500mL
Corning	88-610-20	Culture bag悬浮细胞培养袋	10个/包，10包/箱
Corning	88-702-CB	KM Banker I，尤其适用于淋巴细胞	120mL/瓶
OriGen	CP-10	USP级DMSO二甲基亚砜	10mL/瓶，12瓶/盒
OriGen	CP-70	USP级DMSO二甲基亚砜	70mL/瓶，6瓶/盒
OriGen	CD-50	DMSO/Dextran/remainder water55%二甲基亚砜， 5%右旋糖干40混合液	50mL/瓶，6瓶/盒
Hospira	0409-7248-03	6% Hetastarch in 0.9% Sodium Chloride 羟乙基淀粉氯化钠	500mL/袋
Hospira	0409-7419-03	10% LMD in 0.9% Sodium Chloride IjectionDEX40右旋糖干	500mL/袋

以下是，各种细胞组织培养袋，如需其它型号产品，请详询客服

产品品牌	产品型号	标准容积ML	最大容积ML	宽度	长度	表面积
PermaLife	PL07	7	12	3	6.3	38
PermaLife	PL30	30	50	8.9	6.1	108
PermaLife	PL70	70	145	8.9	9.7	172
PermaLife	PL120	120	265	8.9	14	248
PermaLife	PL240	240	725	14	19.3	540
PermaLife	PL325	325	1100	14	25.9	725
PermaLife	PL500P	500	1500	29.21	18	1052
PermaLife	PL750	750	1500	29.21	26.5	1548
PermaLife	PL1000P	1000	3000	29.21	35	2045
PermaLife	PL2000P	2000	3000	47	45	4230
产品品牌	产品货号	产品名称	宽度cm	长度cm	容积Ml	产品包装
OriGen	CS25	CryoStore 25 EVA冻存袋	9.0	7.3	10-25	24个/箱
OriGen	CS25F	CryoStore 25 EVA冻存袋，F型管路	9.0	7.3	10-25	24个/箱
OriGen	CS25N	CryoStore 25 EVA冻存袋，N型管路	9.0	7.3	10-25	24个/箱
OriGen	CS50	CryoStore 50 EVA冻存袋	7.6	14.5	10-30	24个/箱
OriGen	CS250	CryoStore 250 EVA冻存袋	12.7	15.3	30-70	24个/箱
OriGen	C5500	CryoStore 500 EVA冻存袋	12.7	22.8	55-100	24个/箱
OriGen	CS1000	CryoStore 2000 EVA冻存袋	15.0	28.5	120-275	24个/箱
OriGen	CS2000	CryoStore 2000 EVA冻存袋	23.0	33.5	180-450	24个/箱

以下各种细胞组织培养袋配套2

产品品牌	产品型号	表面积cm2	标准容积ML	最大容积ML	CO2交换g	O2交换g	水分g
OriGen Evolve	EV120	130	70-120	250	1093.5	132.89	0.81
OriGen Evolve	EV1000n	300	100-500	1000	2491 4	302.78	1.86
OriGen Evolve	EV3000n	750	500-2000	3000	6924.7	841.56	5.16
产品品牌	产品货号	产品名称	宽度X高度X深度	每室容积	冷冻容积	小室数量	规格
OriGen	CS30M9	多室冷冻袋	10.8cmx5.5cmx0.9cm	6mL	zuigao30mL	5个	12个/包